The global monoclonal antibodies (mAbs) market was valued at
USD 85.4 billion in 2015 and is expected to reach a value of USD 138.6 billion
by 2024. Increasing R&D pertaining to the development of therapeutic mAbs
coupled with supportive government initiatives is expected to drive the
monoclonal antibodies market growth over the forecast period.
Increasing demand for personalized medicine is a vital factor
responsible for the increasing development of therapeutic antibodies to provide
targeted therapies as every individual responds in a different manner to a
particular treatment. Moreover, related benefits of using mAbs for therapeutic
purposes, including fewer adverse effects, homogeneity, specificity, and
large-scale production, are contributing toward significant market growth.
In addition, the government initiatives to enable cost-effective
production of mAbs is anticipated to propel the emergence of this sector over
the forecast period. For instance, the biomanufacturing initiative byNational
Institute of Standards and Technology in the U.S. provides scientifically sound
regulatory guidelines to ensure effective and safe manufacturing of protein
therapeutics and to support biopharmaceutical manufacturers in offering
low-cost and high-quality protein drugs across the globe.
Full research report on monoclonal antibodies (mAbs) market analysis: http://www.grandviewresearch.com/industry-analysis/monoclonal-antibodies-market
Further Key Findings from the Study Suggest:
·
Human-based mAbs segment is predicted to
grow at a lucrative CAGR in the coming years due to their associated benefits
and numerous R&D activities conducted for further development of human
mAbs. Large number of mAbs of human origin are in phase III clinical trial for
cancer treatment
·
In vitro production of mAbs is anticipated
to show the fastest growth owing to its wide-scale adoption by biologics
manufacturers due to its greater efficiency in cost and time
·
The research institute segment is
anticipated to exhibit profitable growth due to increasing R&D efforts in
the biotech industry as monoclonal antibodies have emerged as a major class of
therapeutics for several human diseases, particularly immunological infectious
diseases and cancer
·
The Asia pacific region has significant
growth potential due to rising government initiatives in this region supporting
the use of mAbs for research and treatment purposes coupled with the surge in
sponsored R&D projects for the development of cost-effective therapeutic
mAbs.
·
For instance, government-led fund
providers, such as National Natural Science Foundation and National Basic
Research Program of China, offer financial support to enterprises and universities
to conduct mAb research and development.
·
The key players serving the monoclonal
antibodies market arePfizer, Inc., GlaxoSmithKline plc, Novartis AG, Merck
& Co., Inc, Amgen, Inc., Abbott Laboratories, AstraZeneca, Eli Lilly and
Company, Mylan N.V., Daiichi Sankyo Company, Ltd., Bayer AG, Bristol Myers
Squibb Co.,Johnson & Johnson Services, Inc., Biogen Inc., Thermo Fisher
Scientific, Inc., Sanofi Genzyme, F. Hoffmann-La Roche Ltd., and Novo Nordisk
A/S.
·
The introduction of advanced methods for
mAb production further encourages the pharmaceutical companies to build their
own product pipeline. According to a study published by NCBI at the end of
2013, approximately 816 companies were involved in therapeutic protein
research.
View more reports
of this category by Grand View Research at: https://www.grandviewresearch.com/industry/biotechnology
Grand View Research has segmented the monoclonal antibodies market by
source type, production, indication, end-use, and region:
Global Monoclonal
Antibodies Source Type Outlook (Revenue, USD Billion, 2013 - 2024)
·
Murine
·
Chimeric
·
Humanized
·
Human
Global Monoclonal
Antibodies Production Type Outlook (Revenue, USD Billion, 2013 - 2024)
·
In Vivo
·
In Vitro
Global Monoclonal
Antibodies Indication Outlook (Revenue, USD Billion, 2013 - 2024)
·
Cancer
·
Autoimmune Diseases
·
Inflammatory Diseases
·
Infectious Diseases
·
Microbial Diseases
·
Others
Global Monoclonal
Antibodies End-use Outlook (Revenue, USD Billion, 2013 - 2024)
·
Hospitals
·
Research Institutes
·
Others
Monoclonal
antibodies Market Regional Outlook (Market Revenue in USD Billion,
2013 - 2024)
·
North America
o U.S.
o Canada
·
Europe
o UK
o Germany
·
Asia Pacific
o Japan
o China
o India
·
Latin America
o Brazil
o Mexico
·
Middle East and Africa
o South Africa
View Press Release of this research
report by Grand View Research: https://www.grandviewresearch.com/press-release/global-monoclonal-antibodies-market
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
For More Information: www.grandviewresearch.com
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
For More Information: www.grandviewresearch.com
No comments:
Post a Comment